Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

1110059M19Rik Inhibitors

Chemical inhibitors of 1110059M19Rik can influence its function through various molecular pathways by targeting specific enzymes and kinases that play a role in its regulation. LY294002 and Wortmannin are two chemical inhibitors that target phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, these chemicals can lead to a decrease in the activity of the AKT signaling pathway, in which 1110059M19Rik participates. This results in reduced phosphorylation and activation of downstream targets and can affect the functioning of 1110059M19Rik. Rapamycin, on the other hand, inhibits mTOR, a key component further downstream in the PI3K/AKT/mTOR pathway. By inhibiting mTOR, Rapamycin can disrupt the signaling cascade necessary for the proper functioning of 1110059M19Rik, leading to its functional inhibition.

In a similar vein, PD98059 and U0126 target the MEK1/2 enzymes, which are upstream regulators of the ERK pathway, a pathway in which 1110059M19Rik is involved. Inhibition of MEK1/2 by these chemicals prevents the activation of ERK, thereby inhibiting the function of 1110059M19Rik. SB203580 and SP600125 selectively inhibit p38 MAP kinase and JNK, respectively, both of which are kinases that can modify the function of 1110059M19Rik through phosphorylation events. SB203580's inhibition of p38 MAP kinase and SP600125's inhibition of JNK lead to an interruption in their respective signaling pathways, affecting the function of 1110059M19Rik. Additionally, Dasatinib and PP2, both Src family kinase inhibitors, can impede the Src kinase-mediated signaling processes, ultimately leading to the functional inhibition of 1110059M19Rik. Lastly, Bisindolylmaleimide I, which inhibits PKC, and Staurosporine, a broad-spectrum kinase inhibitor, can also suppress the function of 1110059M19Rik by inhibiting the kinases that activate or regulate it. Lapatinib's role in inhibiting EGFR and HER2 also leads to a downstream effect on the functional activity of 1110059M19Rik, as EGFR and HER2 are involved in pathways that activate various proteins, including 1110059M19Rik.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 inhibits PI3K, which is involved in the AKT signaling pathway. Since 1110059M19Rik is part of the AKT pathway, inhibition of PI3K will lead to a decrease in AKT activity, thereby inhibiting the function of 1110059M19Rik.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059 inhibits MEK, which is upstream of ERK in the MAPK/ERK pathway. 1110059M19Rik, being part of this pathway, will be functionally inhibited due to the suppression of ERK activation.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 is a specific inhibitor of p38 MAP kinase. By inhibiting p38, the function of 1110059M19Rik is impeded as it operates within the p38 MAPK regulated signaling cascade.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 inhibits JNK, and by doing so, it prevents the JNK-mediated phosphorylation events that would be necessary for the functional activation of 1110059M19Rik within the JNK signaling pathway.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Dasatinib is a Src family kinase inhibitor. Src kinases can phosphorylate substrates involved in the pathway of 1110059M19Rik, and by inhibiting these kinases, Dasatinib indirectly leads to functional inhibition of 1110059M19Rik.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

U0126 is an inhibitor of MEK1/2, and by inhibiting these kinases, it prevents the activation of downstream components in the MAPK/ERK pathway, thus functionally inhibiting 1110059M19Rik which is a part of this pathway.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is another PI3K inhibitor which will lead to a reduction in AKT phosphorylation. This reduction in AKT activity functionally inhibits 1110059M19Rik if AKT is involved in its regulation or function.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin inhibits mTOR, which is a central component of the PI3K/AKT/mTOR pathway. Through mTOR inhibition, Rapamycin can functionally inhibit 1110059M19Rik by disrupting the signaling cascade it is part of.

Bisindolylmaleimide I (GF 109203X)

133052-90-1sc-24003A
sc-24003
1 mg
5 mg
$105.00
$242.00
36
(1)

Bisindolylmaleimide I inhibits PKC, and if 1110059M19Rik is regulated by PKC-dependent signaling, its function will be inhibited due to the suppression of PKC activity.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Lapatinib inhibits EGFR and HER2, which are involved in signaling pathways that can lead to the activation of various downstream proteins, including 1110059M19Rik. Inhibition of EGFR and HER2 will thus inhibit the function of 1110059M19Rik.